Home › Compare › FCODF vs ABBV
FCODF yields 0.38% · ABBV yields 3.06%● Live data
📍 FCODF pulled ahead of the other in Year 9
Combined, FCODF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FCODF + ABBV for your $10,000?
Compagnie de l'Odet operates in the transport and logistics, and communication sectors in France, Africa, the Americas, the Asia-Pacific, and other European countries. The company operates through Transportation and Logistics, Oil Logistics, Communication, and Electricity Storage and Systems segments. The Transportation and Logistics segment provides maritime, and air transport and logistics services. The Oil Logistics segment distributes oil products. The Communication segment engages in the sale of recorded music on physical media or digital form; exploitation of copyrights and services to artists; editing and distribution of pay and free television channels; production, sale, and distribution of motion pictures and TV series; design and publishing of downloadable video games for mobiles and consoles; and provision of ticketing services, and communication and advertising agency consultancy. The Electricity Storage and Systems segment produces and sells electric batteries for electric vehicles, terminals and specialized systems, and plastic films, as well as telecommunications activities. It also manages a portfolio of financial investments. The company was formerly known as Financière de l'Odet SA and changed its name to Compagnie de l'Odet in May 2021. The company was incorporated in 1929 and is headquartered in Paris, France. Compagnie de l'Odet is a subsidiary of Bolloré SE.
Full FCODF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.